> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pediatric Committee to Review Safety of 2 Products
- URL: https://www.fdaweb.com/pediatric-committee-to-review-safety-of-2-products/
- Published: 2017-02-16T12:00:00.000Z
- Updated: 2026-09-14T22:07:02.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138006

*Federal Register* Notice: FDA has announced an amendment to a 3/6-7 Pediatric Advisory Committee. The meeting was first announced in the 1/5 *Federal Register*. The amended notice outlines the products that will undergo pediatric-focused safety reviews as mandated by the Best Pharmaceuticals for Children Act — Nitropress (sodium nitroprusside) and Kuvan (sapropterin dihydrochloride). To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-02-16/pdf/2017-03144.pdf?ref=fdaweb.com).